Technology | January 11, 2010

Novel Stereotactic Radiosurgery Device Treats AMD in Study

IRay System

January 11, 2010 - The first ever masked and sham-controlled study designed to demonstrate the efficacy and safety of investigational stereotactic radiosurgical device for the treatment of wet age-related macular degeneration (AMD) is now underway at seven European sites.

The device delivers radiation dose using the IRay system, a proprietary non-invasive low energy stereotactic X-ray platform that has been in development since early 2007, developed by Oraya Therapeutics, Inc.

The IRay system is an investigational stereotactic radiosurgical device designed specifically to treat diseases of the eye. The single organ focus of Oraya's technology enables precise delivery of low-energy X-rays to treat wet AMD. Designed to maximize patient comfort and precision, the IRay system utilizes a vacuum-coupled contact lens interface, the I-Guide, which holds the eye to maintain stability during treatment, while detecting eye motion. A gating system, which automatically shuts down the device in case of misalignment due to patient movement, is also featured. Because the radiation delivered is low-voltage, comparable to a chest or dental X-ray, the IRay is suitable for use in a typical ophthalmology office setting. The entire patient treatment process requires only a topical anesthetic, and lasts 15 to 20 minutes.

The study, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY).

All patients will have standard of care anti-VEGF drug therapy, and the trial is designed and powered to measure the effect of the radiation adjunct on vision outcomes and on the frequency of anti-VEGF injections. Trial endpoints will be evaluated one year post radiation treatment. Over 60 patients have already been treated in a Phase 1 study of the device, and results from that study led to the design and initiation of this newly announced trial.

Clinical advisor to Oraya and associate professor of ophthalmology at Stanford University, Darius Moshfeghi, M.D., says data from the Phase 1 study showed an excellent safety profile.

Combination therapies as adjuncts to anti-VEGF therapy are showing great promise to improve the overall treatment options and outcomes for wet AMD patients, according Peter Kaiser, M.D., of the Cole Eye Institute at the Cleveland Clinic, who is a renowned expert on new therapies for AMD, and participated in the design of Oraya's European protocol.

For more information: /www.orayainc.com/clinicaltrials.asp and www.clinicaltrials.gov (identifier NCT01016873)

Related Content

more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Surgery and High-Dose SBRT Radiation Can Be Combined to Treat Kidney Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | July 05, 2017
A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the...
ASTRO Issues Guideline for Stereotactic Radiation Use in Early-Stage Lung Cancer
Feature | Lung Cancer | June 23, 2017
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical guideline for the use of...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Stereotactic Radiation Highly Effective for Kidney Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | May 03, 2017
Kidney cancer patients may soon have an alternative to traditional treatments, according to new research at UT...
SBRT, stereotactic body radiation therapy, early-stage lung cancer, patients 80 and older, 2017 Multidisciplinary Thoracic Cancers Symposium, study
News | Stereotactic Body Radiation Therapy (SBRT) | March 20, 2017
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely...
prostate cancer, partial gland, SBRT, clinical trial, UH Hospitals
News | Stereotactic Body Radiation Therapy (SBRT) | April 28, 2016
Physicians at University Hospitals Seidman Cancer Center (Cleveland) have started a clinical trial using a new form of...
prostate cancer, stereotactic body radiation therapy, SBRT, cure rate, UT Southwestern Study
News | Prostate Cancer | April 19, 2016
A five-year study shows that stereotactic body radiation therapy (SBRT) offers a higher cure rate for prostate cancer...
Overlay Init